Ongoing treatment with anti-vascular endothelial growth factor (VEGF) injections or photodynamic therapy (verteporfin) is, to date, the primary means of managing and treating AMD. Several non-profit organizations also offer patient access programs.
Here is a brief description of some of the patient-assistance programs (PAPs) specific to retinal disorders/AMD. Other resources are available from organizations other than the pharmaceutical company:
Beginning in 2017, the HealthWell Foundation (https://www.healthwellfoundation.org/) launched a Macular Degeneration Fund to provide copayment and premium assistance to eligible patients living with macular degeneration. Under the fund, HealthWell provides up to $4,000 to individuals who have annual household incomes up to 400% of the Federal Poverty Level (FPL) to assist with out-of-pocket costs for treatment of their disease. (Of potential note, this fund also covers off-label intravitreal bevacizumab.) Eligibility criteria includes being currently treated for AMD (wet or dry), insurance that covers medication, income falling within the stated parameters, and receiving treatment in the United States.